Medtronic (NYSE:MDT) Issues FY 2025 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 5.440-5.500 for the period, compared to the consensus estimate of 5.450. The company issued revenue guidance of $33.5 billion-$33.6 billion, compared to the consensus revenue estimate of $33.6 billion.

Wall Street Analysts Forecast Growth

MDT has been the subject of a number of research reports. Needham & Company LLC reiterated a “hold” rating on shares of Medtronic in a report on Monday. Citigroup lifted their target price on Medtronic from $85.00 to $92.00 and gave the company a “neutral” rating in a research report on Tuesday, October 1st. Oppenheimer raised their price target on shares of Medtronic from $92.00 to $94.00 and gave the stock a “market perform” rating in a research note on Wednesday, August 21st. Wells Fargo & Company lifted their price objective on shares of Medtronic from $105.00 to $106.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Finally, Robert W. Baird increased their target price on shares of Medtronic from $90.00 to $96.00 in a report on Friday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $95.80.

Medtronic Price Performance

MDT opened at $87.64 on Tuesday. Medtronic has a fifty-two week low of $74.66 and a fifty-two week high of $92.68. The firm has a 50-day moving average of $89.42 and a 200 day moving average of $84.82. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.61 and a current ratio of 2.13. The firm has a market cap of $112.39 billion, a P/E ratio of 29.61, a PEG ratio of 2.50 and a beta of 0.84.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, August 20th. The medical technology company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.03. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. The firm had revenue of $7.97 billion for the quarter, compared to analysts’ expectations of $7.90 billion. During the same period in the prior year, the business posted $1.20 earnings per share. The company’s revenue was up 3.4% on a year-over-year basis. On average, research analysts expect that Medtronic will post 5.44 EPS for the current year.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.